FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
120 letters match. Newest first.
-
DrugsNewman Clinic, PLLC dba Newman Clinic
FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsNewSelf Limited dba NewSelf
FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.
Low -
Drugs24HrDoc, Inc. dba 24HrDoc
FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
Medium -
DrugsAlan Health Technologies Inc. dba Alan
FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.
Low -
DrugsDripgym Mobile Parent, LLC dba Amp Health
FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.
Low -
DrugsBelle Health LLC dba Belle
FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.
Low -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsBluefitMD
FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.
Low -
DrugsDeluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics
FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.
Low -
DrugsAspen Aesthetics dba Fifty 410
FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.
Low -
DrugsFitRX, LLC dba FitRx
FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
Medium -
DrugsGenesis Health International Inc. dba Genesis
FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.
Low -
BiologicsDynamic Stem Cell Therapy
FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.
High risk -
DevicesExThera Medical Corporation
ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.
High risk -
DrugsMedisourceRx
MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.
Medium -
AnimalElanco Animal Health USA
FDA says Elanco's Pradalex ads misbrand the livestock antibiotic by claiming first-line use and "all relevant pathogen" coverage.
Medium -
BiologicsGenetrace
FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.
High risk -
BiologicsGenovate
FDA warns Genovate over selling an unapproved HIV dried-blood-spot self-collection kit without marketing authorization.
High risk -
DrugsAgebox Inc.
Agebox Inc. sells iKids-Growth children's supplements containing the undeclared, unapproved drug ibutamoren, making them unapproved and misbranded drugs.
High risk -
DrugsExela Pharma Sciences LLC
Unapproved New Drug/Compounding/Misbranding